The U.S. Food and Drug Administration (FDA) has accepted for filing Oscient Pharmaceuticals’ (Nasdaq: OSCI) supplemental New Drug Application (sNDA) seeking marketing approval for the use of FACTIVE(R) (gemifloxacin mesylate) tablets (320 mg once-daily) for the five-day treatment of mild to moderate community-acquired pneumonia (CAP). The FDA has refused to accept the sNDA filing for the five-day treatment of acute bacterial sinusitis (ABS).